MedPacto, FDA Approval for Phase 1/2 IND of Bactosertib Monotherapy in Osteosarcoma Patients

[Asia Economy Reporter Minji Lee] MedPacto announced on the 8th that it has received approval from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial plan of Vactosertib monotherapy targeting adolescent and adult patients suffering from recurrent refractory and advanced osteosarcoma.